MASLD, a liver disease linked to obesity and poor lifestyle, is rising among children. Often symptomless early on, it can ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A collection of videos, study abstracts, and other resources all focused on disparities in obesity. Obesity is independently ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...